Novartis Certican Short-Term Renal Safety Study Suggested By Panel

A short-term renal toxicity study establishing the safety of Novartis' Certican with lower doses of cyclosporine could sway members of FDA's Cardiovascular & Renal Drugs Advisory Committee to recommend approval of the immunosuppressant in heart transplantation

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet